Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $132000.0.

  • Keros Therapeutics' Capital Expenditures fell 6580.31% to $132000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 2185.07%. This contributed to the annual value of $1.9 million for FY2024, which is 2163.15% down from last year.
  • Latest data reveals that Keros Therapeutics reported Capital Expenditures of $132000.0 as of Q3 2025, which was down 6580.31% from $720000.0 recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Capital Expenditures registered a high of $1.1 million during Q1 2023, and its lowest value of $132000.0 during Q3 2025.
  • Moreover, its 5-year median value for Capital Expenditures was $351000.0 (2022), whereas its average is $425105.3.
  • In the last 5 years, Keros Therapeutics' Capital Expenditures surged by 172142.86% in 2021 and then crashed by 6580.31% in 2025.
  • Over the past 5 years, Keros Therapeutics' Capital Expenditures (Quarter) stood at $159000.0 in 2021, then surged by 120.75% to $351000.0 in 2022, then surged by 54.13% to $541000.0 in 2023, then tumbled by 46.58% to $289000.0 in 2024, then crashed by 54.33% to $132000.0 in 2025.
  • Its Capital Expenditures was $132000.0 in Q3 2025, compared to $720000.0 in Q2 2025 and $565000.0 in Q1 2025.